Primary Prophylaxis With Biosimilar Filgrastim for Patients at Intermediate Risk for Febrile Neutropenia: A Cost-Effectiveness Analysis

Temporary COVID-19 guideline recommendations have recently been issued to expand the use of colony-stimulating factors in patients with cancer with intermediate to high risk for febrile neutropenia (FN). We evaluated the cost-effectiveness of primary prophylaxis (PP) with biosimilar filgrastim-sndz...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Edward, Mezzio, Dylan J., Campbell, David, Campbell, Kim, Lyman, Gary H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2021
Materias:
Special Series: Quality Care Symposium
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8360497/
https://www.ncbi.nlm.nih.gov/pubmed/33793342
http://dx.doi.org/10.1200/OP.20.01047

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8360497/
https://www.ncbi.nlm.nih.gov/pubmed/33793342
http://dx.doi.org/10.1200/OP.20.01047

Ejemplares similares